Home LiteratureArticle Details
PMID: 20198110 Published · ppublish English Journal Article

Ebolavirus glycoprotein structure and mechanism of entry.

Future virology ·Vol. 4 ·No. 6 ·2009-00-00 ·Pages 621-635

Lee JE, Saphire EO

Abstract

Ebolavirus (EBOV) is a highly virulent pathogen capable of causing a severe hemorrhagic fever with 50-90% lethality. The EBOV glycoprotein (GP) is the only virally expressed protein on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion. Hence, the EBOV GP is a critical component of vaccines as well as a target of neutralizing antibodies and inhibitors of attachment and fusion. The crystal structure of the Zaire ebolavirus GP in its trimeric, prefusion conformation (3 GP(1) plus 3 GP(2)) in complex with a neutralizing antibody fragment, derived from a human survivor of the 1995 Kikwit outbreak, was recently determined. This is the first near-complete structure of any filovirus glycoprotein. The overall molecular architecture of the Zaire ebolavirus GP and its role in viral entry and membrane fusion are discussed in this article.

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lee Jeffrey E
Department of Immunology & Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA, Tel.: +1 858 784 7976.
Saphire Erica Ollmann
References (107)
107 references, click to expand
  1. Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts.
    J Biol Chem. 2007 Sep 14;282(37):27306-27314 PMID: 17545161
  2. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.
    Crit Rev Biochem Mol Biol. 2008 May-Jun;43(3):189-219 PMID: 18568847
  3. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.
    J Infect Dis. 1999 Feb;179 Suppl 1:S218-23 PMID: 9988187
  4. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  5. Association of the caveola vesicular system with cellular entry by filoviruses.
    J Virol. 2002 May;76(10):5266-70 PMID: 11967340
  6. Covalent modifications of the ebola virus glycoprotein.
    J Virol. 2002 Dec;76(24):12463-72 PMID: 12438572
  7. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function.
    J Virol. 1999 Feb;73(2):1419-26 PMID: 9882347
  8. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.
    Nature. 1981 Jan 29;289(5796):366-73 PMID: 7464906
  9. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    J Virol. 1999 Jul;73(7):6024-30 PMID: 10364354
  10. [Development and study of the properties of immunoglobulin against Ebola fever].
    Vopr Virusol. 1995 Nov-Dec;40(6):270-3 PMID: 8686265
  11. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.
    J Virol. 2000 May;74(10):4933-7 PMID: 10775638
  12. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding.
    J Virol. 2009 Apr;83(7):2883-91 PMID: 19144707
  13. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.
    J Virol. 2005 Aug;79(16):10442-50 PMID: 16051836
  14. Herpes simplex virus: receptors and ligands for cell entry.
    Cell Microbiol. 2004 May;6(5):401-10 PMID: 15056211
  15. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival.
    J Infect Dis. 1999 Feb;179 Suppl 1:S24-7 PMID: 9988161
  16. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.
    J Virol. 2003 Jan;77(2):1069-74 PMID: 12502822
  17. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.
    Mol Cell. 1998 Nov;2(5):605-16 PMID: 9844633
  18. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.
    PLoS Pathog. 2008 Nov;4(11):e1000212 PMID: 19023410
  19. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L.
    Virology. 2006 Mar 15;346(2):251-7 PMID: 16460775
  20. Antibody recognition of a highly conserved influenza virus epitope.
    Science. 2009 Apr 10;324(5924):246-51 PMID: 19251591
  21. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation.
    Cell. 1998 Oct 30;95(3):409-17 PMID: 9814710
  22. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.
    J Virol. 2002 Mar;76(5):2518-28 PMID: 11836430
  23. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates.
    J Virol. 2007 Mar;81(6):2995-8 PMID: 17229700
  24. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.
    J Virol. 2004 Mar;78(6):2943-7 PMID: 14990712
  25. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
    J Virol. 2001 May;75(10):4649-54 PMID: 11312335
  26. Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding.
    Virology. 2008 Mar 30;373(1):189-201 PMID: 18083206
  27. A system for functional analysis of Ebola virus glycoprotein.
    Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14764-9 PMID: 9405687
  28. Public health assessment of potential biological terrorism agents.
    Emerg Infect Dis. 2002 Feb;8(2):225-30 PMID: 11897082
  29. Experimental vaccine may have saved Hamburg scientist from Ebola fever.
    BMJ. 2009 Mar 23;338:b1223 PMID: 19307268
  30. Structural basis of West Nile virus neutralization by a therapeutic antibody.
    Nature. 2005 Sep 29;437(7059):764-9 PMID: 16193056
  31. Fruit bats as reservoirs of Ebola virus.
    Nature. 2005 Dec 1;438(7068):575-6 PMID: 16319873
  32. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.
    Curr Opin Struct Biol. 2009 Aug;19(4):408-17 PMID: 19559599
  33. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.
    J Virol. 2007 Jul;81(14):7702-9 PMID: 17475648
  34. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway.
    J Virol. 2005 Jan;79(1):547-53 PMID: 15596847
  35. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  36. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer.
    Virology. 1998 Oct 25;250(2):408-14 PMID: 9792851
  37. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.
    J Biol Chem. 2006 Jun 9;281(23):15951-8 PMID: 16595665
  38. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
    J Infect Dis. 1999 Feb;179 Suppl 1:S224-34 PMID: 9988188
  39. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.
    PLoS Pathog. 2007 Jan;3(1):e9 PMID: 17238286
  40. The mature avian leukosis virus subgroup A envelope glycoprotein is metastable, and refolding induced by the synergistic effects of receptor binding and low pH is coupled to infection.
    J Virol. 2004 Feb;78(3):1403-10 PMID: 14722295
  41. Processing of the Ebola virus glycoprotein by the proprotein convertase furin.
    Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7 PMID: 9576958
  42. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
    Nat Struct Mol Biol. 2009 Mar;16(3):265-73 PMID: 19234466
  43. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    J Virol. 2009 Jul;83(14):7296-304 PMID: 19386702
  44. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.
    J Infect Dis. 1999 Feb;179 Suppl 1:S177-87 PMID: 9988182
  45. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.
    Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81 PMID: 16081529
  46. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus.
    Chembiochem. 2006 Oct;7(10):1605-11 PMID: 16977667
  47. Discovery of swine as a host for the Reston ebolavirus.
    Science. 2009 Jul 10;325(5937):204-6 PMID: 19590002
  48. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level.
    J Gen Virol. 2006 May;87(Pt 5):1247-1257 PMID: 16603527
  49. Recombinant human monoclonal antibodies to Ebola virus.
    J Infect Dis. 1999 Feb;179 Suppl 1:S235-9 PMID: 9988189
  50. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.
    J Virol. 2006 Apr;80(8):4174-8 PMID: 16571833
  51. Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry.
    Virus Res. 2006 Nov;121(2):205-14 PMID: 16839637
  52. Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.
    J Virol. 2003 Dec;77(24):13433-8 PMID: 14645601
  53. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.
    Nature. 2006 Jan 5;439(7072):38-44 PMID: 16397490
  54. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.
    Virology. 2000 Dec 5;278(1):20-6 PMID: 11112476
  55. Role of endocytosis and cathepsin-mediated activation in Nipah virus entry.
    Virology. 2008 Jun 5;375(2):391-400 PMID: 18342904
  56. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein.
    J Virol. 2005 Oct;79(20):12714-20 PMID: 16188974
  57. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.
    J Mol Biol. 2008 Jan 4;375(1):202-16 PMID: 18005986
  58. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.
    Science. 2005 Jun 10;308(5728):1643-5 PMID: 15831716
  59. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease.
    EMBO J. 1992 Jul;11(7):2407-14 PMID: 1628614
  60. Epitopes involved in antibody-mediated protection from Ebola virus.
    Science. 2000 Mar 3;287(5458):1664-6 PMID: 10698744
  61. Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP.
    Biochem Biophys Res Commun. 2004 Oct 15;323(2):696-702 PMID: 15369806
  62. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Nature. 2008 Jul 10;454(7201):177-82 PMID: 18615077
  63. Structure of influenza haemagglutinin at the pH of membrane fusion.
    Nature. 1994 Sep 1;371(6492):37-43 PMID: 8072525
  64. Tyro3 family-mediated cell entry of Ebola and Marburg viruses.
    J Virol. 2006 Oct;80(20):10109-16 PMID: 17005688
  65. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines.
    J Virol. 1998 Apr;72(4):3155-60 PMID: 9525641
  66. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  67. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.
    J Gen Virol. 2000 Sep;81(Pt 9):2155-2159 PMID: 10950971
  68. Ectodomain shedding of the glycoprotein GP of Ebola virus.
    EMBO J. 2004 May 19;23(10):2175-84 PMID: 15103332
  69. Viral membrane fusion.
    Nat Struct Mol Biol. 2008 Jul;15(7):690-8 PMID: 18596815
  70. Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses.
    Cell. 1996 May 17;85(4):477-8 PMID: 8653783
  71. The Role of histidine residues in low-pH-mediated viral membrane fusion.
    Structure. 2006 Oct;14(10):1481-7 PMID: 17027497
  72. The antiviral activity of antibodies in vitro and in vivo.
    Adv Immunol. 2001;77:195-262 PMID: 11293117
  73. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.
    Virology. 2009 Jan 20;383(2):237-47 PMID: 19013626
  74. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases.
    Virology. 1995 Dec 20;214(2):421-30 PMID: 8553543
  75. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.
    Arch Virol Suppl. 1996;11:135-40 PMID: 8800795
  76. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2662-7 PMID: 10077567
  77. Mechanism of membrane fusion by viral envelope proteins.
    Adv Virus Res. 2005;64:231-61 PMID: 16139596
  78. Structure of the dengue virus envelope protein after membrane fusion.
    Nature. 2004 Jan 22;427(6972):313-9 PMID: 14737159
  79. Antiviral antibody responses: the two extremes of a wide spectrum.
    Nat Rev Immunol. 2006 Mar;6(3):231-43 PMID: 16498452
  80. Roles of a conserved proline in the internal fusion peptide of Ebola glycoprotein.
    FEBS Lett. 2004 Jul 2;569(1-3):261-6 PMID: 15225645
  81. Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion.
    Virology. 2008 Jan 20;370(2):403-14 PMID: 17936324
  82. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
    J Virol. 2002 Jun;76(12):6408-12 PMID: 12021376
  83. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S400-3 PMID: 17940976
  84. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.
    J Infect Dis. 1999 Feb;179 Suppl 1:S18-23 PMID: 9988160
  85. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.
    Virology. 2003 Jan 5;305(1):115-23 PMID: 12504546
  86. Ebola sGP--the first viral glycoprotein shown to be C-mannosylated.
    Virology. 2007 Nov 10;368(1):83-90 PMID: 17659315
  87. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity.
    J Virol. 2007 Dec;81(24):13378-84 PMID: 17928356
  88. Return to the past: the case for antibody-based therapies in infectious diseases.
    Clin Infect Dis. 1995 Jul;21(1):150-61 PMID: 7578724
  89. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.
    J Virol. 1998 Aug;72(8):6442-7 PMID: 9658086
  90. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G.
    Science. 2007 Feb 9;315(5813):843-8 PMID: 17289996
  91. Towards a vaccine against Ebola virus.
    Expert Rev Vaccines. 2003 Dec;2(6):777-89 PMID: 14711361
  92. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
    Nature. 1992 Nov 26;360(6402):358-61 PMID: 1360148
  93. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3602-7 PMID: 8622982
  94. Structural basis of viral invasion: lessons from paramyxovirus F.
    Curr Opin Struct Biol. 2007 Aug;17(4):427-36 PMID: 17870467
  95. Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G.
    Science. 2006 Jul 14;313(5784):187-91 PMID: 16840692
  96. Hemorrhagic fever viruses as biological weapons: medical and public health management.
    JAMA. 2002 May 8;287(18):2391-405 PMID: 11988060
  97. The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells.
    Blood. 2007 Jun 15;109(12):5337-45 PMID: 17339424
  98. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.
    Nature. 1995 May 25;375(6529):291-8 PMID: 7753193
  99. Crystal structure of glycoprotein B from herpes simplex virus 1.
    Science. 2006 Jul 14;313(5784):217-20 PMID: 16840698
  100. Comprehensive analysis of ebola virus GP1 in viral entry.
    J Virol. 2005 Apr;79(8):4793-805 PMID: 15795265
  101. Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus.
    Virology. 1999 Dec 5;265(1):164-71 PMID: 10603327
  102. Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S251-8 PMID: 17940957
  103. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
    PLoS Pathog. 2008 Nov;4(11):e1000225 PMID: 19043556
  104. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
    Nat Med. 2000 Aug;6(8):886-9 PMID: 10932225
  105. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
    Nat Med. 2005 Jul;11(7):786-90 PMID: 15937495
  106. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.
    J Virol. 2002 Jul;76(13):6841-4 PMID: 12050398
  107. [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever].
    Vopr Virusol. 1994 Mar-Apr;39(2):82-4 PMID: 8017061
Article Info
Journal
Future virology
Abbr.
Future Virol
ISSN
1746-0794
DOI
10.2217/fvl.09.56
Published
2009-00-00
Pages
621-635
Language
English
Region
England
NLM ID
101278124
PMCID
PMC2829775
Grants
NIAID NIH HHS · R21 AI053423-01 · United States
NIAID NIH HHS · R01 AI081982 · United States
NIAID NIH HHS · R01 AI067927 · United States
NIAID NIH HHS · R01 AI081982-01A1 · United States
NIAID NIH HHS · R01 AI067927-04 · United States
External Links
PubMed source DOI: 10.2217/fvl.09.56 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2